Subcutaneous version of risperidone delays relapse to schizophrenia.

The article focuses on a Phase 3 study evaluating the efficacy and safety of a subcutaneous formulation of risperidone in patients with schizophrenia. Topics discussed include the promising potential of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, as a treatment for adults with attention-deficit hyperactivity disorder (ADHD).